报价延迟最少15分钟:2025/12/08 18:29 EST
盘后时段
|
||||
|
0.2956 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.23/-0.07
|
|
企业价值
41.50M
|
| 资产负债 |
|
每股账面净值
-0.28
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.23M
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. |
